Decades of scientific research have given ALK-Abelló a leading position in the market for allergy vaccination. The company's core business is injection-based and drop-based allergy vaccines. In future the company will increasingly focus on tablet-based vaccines that give more patients access to convenient baseline treatment of their allergies.

In January and October 2005 ALK-Abelló presented a number of results from clinical studies of the company's tablet-based vaccine against grass pollen allergy, GRAZAX^®. The findings are the latest in the series of favourable results which have successfully demonstrated and confirmed in recent years that GRAZAX^® is an effective, safe and convenient treatment that improves patients’ quality of life. The application for regulatory approval of the tablet filed by ALK-Abelló with the Swedish authorities in June 2004 is still pending. ALK-Abelló’s expectation of being able to launch GRAZAX^® on the first European markets in late 2006 is unchanged.

Pipeline

Product type

Active ingredient

Indication

Research

Pre-clinical

Phase I

Phase II

Phase III

GRAZAX®

Biological grass pollen allergen

Rhinit

Tablet

Biological house dust mite allergen

Rhinit/ asthma

Tablet

Biological ragweed allergen

Rhinit

Tablet

Biological birch pollen allergen

Rhinit

Recombinant allergy vaccine

Rhinit/ asthma

Acquisitions and collaborations
ALK-Abelló is well prepared for the launch of these new tablet-based vaccines and the new marketing challenges which they entail. At the end of May 2005, ALK-Abelló's position was strengthened further by the acquisition of the French company Allerbio. France is the second-largest market for allergy vaccines after Germany.

The acquisition of Allerbio is a natural step in ALK-Abelló's further development to be the leader in research, development and production, as well as marketing and sales, in its particular niche.